Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach.
Ángel L MontejoRubén de AlarcónNieves PrietoJosé Mª AcostaBárbara BuchLaura MontejoPublished in: Journal of clinical medicine (2021)
Antipsychotic medication can be often associated with sexual dysfunction (SD). Given its intimate nature, treatment emergent sexual dysfunction (TESD) remains underestimated in clinical practice. However, psychotic patients consider sexual issues as important as first rank psychotic symptoms, and their disenchantment with TESD can lead to important patient distress and treatment drop-out. In this paper, we detail some management strategies for TESD from a clinical perspective, ranging from prevention (carefully choosing an antipsychotic with a low rate of TESD) to possible pharmacological interventions aimed at improving patients' tolerability when TESD is present. The suggested recommendations include the following: prescribing either aripiprazole or another dopaminergic agonist as a first option antipsychotic or switching to it whenever possible. Whenever this is not possible, adjunctive treatment with aripiprazole seems to also be beneficial for reducing TESD. Some antipsychotics, like olanzapine, quetiapine, or ziprasidone, have less impact on sexual function than others, so they are an optimal second choice. Finally, a variety of useful strategies (such as the addition of sildenafil) are also described where the previous ones cannot be applied, although they may not yield as optimal results.
Keyphrases
- end stage renal disease
- clinical practice
- chronic kidney disease
- ejection fraction
- newly diagnosed
- mental health
- oxidative stress
- bipolar disorder
- healthcare
- prognostic factors
- primary care
- peritoneal dialysis
- physical activity
- emergency department
- randomized controlled trial
- case report
- pulmonary hypertension
- patient reported outcomes
- patient reported
- open label
- combination therapy
- decision making
- double blind